California-based genetic testing company Guardant Health announced an underwritten public offering of 12.5 million common shares at a price of USD 28 per share, with expected gross proceeds of USD 350 million. This brings the total funds raised to USD 900 million.
The company has also granted a 30-day purchase option on an additional 1.9 million shares to underwriters at the same price. The offering window is expected to close on May 25, 2023.
The use of funds was not disclosed.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.